Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Klus Pharma Inc.

Sujun Deng

Jingyi Wang

Tongtong Xue

Liang Xiao

Dengnian Liu

Cheng Wang

Haijun Tian

Hong Li

Hu Long

Chunxia Zhao

Marc Peter Ciucci

Yong Zheng

Provided herein is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding the antibody and fragment, and method for preparing the antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Also provided herein is a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs for the prevention and/or treatment of tumors.

Antibody and use thereof

The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Anti-FXI/FXIa antibody and use thereof

Growing community of inventors

Cranbury, NJ, United States of America

Sujun Deng